IMMUNOSCORE® Immunity Assessed - Personalized Treatment

Find out how to gain easy access to Immunoscore® test Click here to discover

Why Immunoscore®?

Immunoscore®* is an in vitro diagnostic test predicting the risk of relapse in early stage colon cancer patients, by measuring the host immune response at the tumor site.

It is a risk-assessment tool that provides independent and superior prognostic value than the usual tumor risk parameters, and should be used as an adjunct to the TNM classification (Pagès F et al. The Lancet 2018, Sinicrope F et al. J Clin Oncol 2018). Immunoscore® can thus improve individual patient treatment strategies, particularly the modulation of adjuvant chemotherapy in stage II and stage III.

a) SITC International study results, The Lancet May 2018
b) N0147 study results, ASCO 17 & ASCO GI 18

* CE-IVD for European Community countries, performed in CLIA certified laboratory for the US.

Immunoscore®
Material: FFPE block or FFPE slides from tumor resection
Target: CD3+ & CD8+ T cells 
Location: Center and periphery of the tumor
Technology: Image Analysis

The Immunoscore® scoring has been defined in a large international SITC-led retrospective validation study conducted on more than 2500 St I-III CC patients (Pagès et al, The Lancet May 2018).

Immunoscore® under its CE-IVD version is the first immune scoring diagnostic tests used in routine by pathology labs leveraging advanced image analysis. The accuracy and robustness of the test relies on precise counting of positive immune cells in predefined regions and automatic calculation of Immunoscore® for each patient based on specific algorithm.

Download general presentation of Immunoscore® (EU version)

Download general presentation of Immunoscore® (US version)

Download Immunoscore® white paper

Clinical Utility

Immunoscore® is a test predicting the risk of relapse of patients with localized CC to help guiding treatment strategies. By evaluating the immune reaction at the tumor site, it provides independent and superior prognostic value to usual risk factors.

Largest contribution of Immunoscore® (47%) to survival risk

Figures extracted from Pagès F et al. The Lancet 2018

This information supports decision about adjuvant chemotherapy need (stage II) and duration of treatment (stage III).

In the large Immunoscore® SITC study (more than 2,500 stage I-III patients), Immunoscore® was strongly predictive of the patient outcome and surpassed the TNM classification prognostic performance.

Among stage II patients (n = 1,434), Immunoscore® identified a subgroup of high-risk patients (Immunoscore® Low) with a significantly higher risk of recurrence at 5 years (23% vs 8% in patients with Immunoscore® High).

TTR in Stage II untreated patients according to clinic-pathological risk

  • Untreated high-risk patients with High Immunoscore® have good clinical outcome similar to Low-risk patients (5Y TTR of 87.4 vs 89.1).
  • 7 out of 10 patients(n=438/630) with high-risk features might be spared from chemotherapy.

Immunoscore® confirms its ability to sharpen clinico-pathological risk features.

  • Discrepancy between MSI/MSS status and Immunoscore® results has been identified for 1 out of 5 patients regarding the DFS(n=27-MSI;129-MSS/841).
  • Patients’ survival is driven by Immunoscore® regardless of their microsatellite stability status (MSI or MSS)

Use Immunoscore® in addition of MSI/MSS status would improve the management of Stage II colon cancer patients.

 

In a retro-prospective study from the prospective NCCTG N0147 clinical trial, Immunoscore® has been tested on 600 resected tumors of stage III CC patients from the FOLFOX arm.

DFS in Stage III

 

  • Overall, patients with High Immunoscore® have a significantly better DFS(HR=0.59, 95% CI, p=0.0013).
  • Among the low-risk group (T1-3 N1), 1 out of 2 patients have high risk of relapse (Low Immunoscore, n=153/287) associated with significantly worse 3 years DFS (DFS at 3 years=78% vs 92%).

These data demonstrate the ability of Immunoscore® to further refine prognostication and was confirmed in the prospective IDEA France cohort study.

Furthermore, in the prospective IDEA France cohort study only patients with a High Immunoscore® did benefit from 6 months of FOLFOXtreatment compared with 3 months, both in low (T1-3, N1) and high (T4 and/or N2) clinical risk groups.

Stage III colon cancer patients with Immunoscore Low had no additional benefit to a longer treatment duration.



A comprehensive body of clinical evidence

  • Immunoscore® surpasses TNM for prediction of tumor recurrence and survival in CRC patients.
  • Stage II CC patients with Immunoscore-Low have a higher risk of recurrence.
  • Immunoscore® is a stronger predictor of survival than MSI in CC.
  • Stage III CC patients with Immunoscore-High have a lower risk of recurrence regardless of the MSI status.
  • Immunoscore® provides prognostic information in low and high T/N risk subsets of Stage III CC.

 

See publications
Click here

HalioDx is conducting multiple studies to further support the Immunoscore®-based risk assessment for CC patients management.


Discover how Immunoscore® is predicting the risk of relapse in localized colon cancer in a short video
Dr Su Pin Choo (Curie Oncology, Singapore) presenting Immunoscore as the tool to identify with confidence who really needs chemotherapy in stage II and who will benefit from 3 versus 6 months of chemotherapy in stage III Colon Cancer
Dr Juan Manuel O’Connor (Instituto Alexander Fleming in Buenos Aires, Argentina) testifies about the challenges to manage early colon cancer patients and the added-value of using Immunoscore in routine practice

How to Order

Your contact:


HalioDx

Oncologists and patients are invited to contact HalioDx which market and distribute Immunoscore® assay in your country.


Luminy Biotech Entreprises
163 Avenue de Luminy
13288 Marseille Cedex 9
FRANCE

Phone: +33 (0) 4 91 29 30 90

 www.haliodx.com

 contact customer service by mail



Immunoscore® workflow

Interested in ordering Immunoscore® ? contact us

Scientific Data

A comprehensive body of clinical evidence

Immunoscore® surpasses TNM for prediction of tumor recurrence and survival in CRC patients.

Pagès F, Mlecnik B, Marliot F et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018; 391 (10135)

Kirilovsky A, Marliot F, El Sissy C et al. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol. 2016;28(8)

Mlecnik B, Tosolini M, Kirilovsky A et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6)

Pagès F, Kirilovsky A, Mlecnik B et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27(35)

Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795)

Stage II CC patients with Immunoscore-Low have a higher risk of recurrence.

Pagès F, Mlecnik B, Marliot F et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018; 391 (10135)

Immunoscore® is a stronger predictor of survival than MSI in CC.

Pagès F, Mlecnik B, Marliot F et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018; 391 (10135)

Mlecnik B, Bindea G, Angell HK et al. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. Immunity.2016;15;44(3)

Stage III CC patients with Immunoscore-High have a lower risk of recurrence regardless of the MSI status.

Sinicrope F, Shi Q, Hermitte F et al. Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N047 (Alliance). J Clin Oncol. 2017; 35:15s (suppl; abstr 3579)

Immunoscore® provides prognostic and predictive information in low and high T/N risk subsets of Stage III CC.

Sinicrope F, Shi Q, Hermitte F et al. Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer JNCI Cancer Spectrum, 2020; Volume 4, Issue 3, June 2020

Pages F, Andre T, Taieb J et al. Prognostic and Predictive Value of the Immunoscore in Stage III Colon Cancer Patients Treated With Oxaliplatin in the Prospective IDEA France PRODIGE-GERCOR Cohort Study Ann Oncol. 2020; Apr 12;S0923-7534(20)36415-2

Sinicrope F, Shi Q, Hermitte F et al. Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance). J Clin Oncol. 2018; 36:4s (suppl; abstr 614)


Resources


#Immunoscore® Colon
Video

#video | Oct. 2020

Dr Tony Dhillon (UK) presenting Immunoscore at the Digestive Cancers Europe Scientific Update: Role of the Immune Response in Early Stage Colorectal Cancers
#Immunoscore® Colon
Video

#video | Oct. 2020

Testimonial: Dr Su Pin Choo (Curie Oncology, Singapore) on the utility of Immunoscore in early stage Colon Cancer
#Immunoscore® Colon
Video

#video | Oct. 2020

Managing colorectal cancer patients in the COVID-19 era with Drs Benjamin Weinberg (USA), Matías Chacón and Juan Manuel O’Connor (both Argentina)
#Immunoscore® Colon
Publication

#publication | Sep. 2020

Mlecnik B Bifulco C, Bindea G, et al.

Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer

J Clin Oncol.

#Immunoscore® Colon
Publication

#publication | Aug. 2020

El Sissy C, Kirilovsky A, Van den Eynde M et al.

A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy

Clin Cancer Res

#Immunoscore® Colon
Publication

#publication | Aug. 2020

F Pages, J Taieb, P Laurent-Puig, and J Galon

The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions

OncoImmunology

#Immunoscore® Colon
Publication

#publication | Aug. 2020

Bruni D, K Angell H and Galon J

The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy

Nature Reviews Cancer

#Immunoscore® Colon
Video

#video | Jul. 2020

Immunoscore® highlights at ESMO GI. Presentations of Dr Le Bagousse and Jérôme Galon, PhD
#Immunoscore® Colon
Publication

#publication | Jul. 2020

A Lanzi,F.A Sinicrope, A.B Benson, and J Galon

The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions

OncoImmunology

#Immunoscore® Colon
Publication

#publication | Jun. 2020

A Lanzi,F Pages, C Lagorce-Pages, and J Galon

The consensus immunoscore: toward a new classification of colorectal cancer

OncoImmunology

#Immunoscore® Colon
Publication

#publication | Jun. 2020

O’Connor JM, Esteso F & Chacón M

Official French SARS-CoV-2 guidelines for cancer patients, a triage solution with precision medicine

Future Medicine

#Immunoscore® Colon
Video

#video | Jun. 2020

Testimonial: Dr Juan Manuel O’Connor (Instituto Alexander Fleming in Buenos Aires, Argentina) on the use of Immunoscore in routine practice in managing early Colon Cancer
#Immunoscore® Colon
E-news

#e-news | Jun. 2020

Factsheet Immunoscore® & COVID-19 Colon Cancer Guidelines
#Immunoscore® Colon
Poster

#poster | May. 2020

Poster presented at ASCO20 Virtual Scientific meeting#ASCO20

Immunoscore is the most powerful parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients Abstract 4105

#Immunoscore® Colon
Publication

#publication | May. 2020

Marliot F, Chen X, Kirilovsky A et al.

Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer

BMJ

#Immunoscore® Colon
E-news

#e-news | May. 2020

Expert Opinion: The Role of Microbiota and its Impact on the Tumor Microenvironment in Colorectal Cancer | Dr Benjamin A. Weinberg, MD, Oncologist in Georgetown, Washington DC
#Immunoscore® Colon
E-news

#e-news | Apr. 2020

Expert Opinion: Immunity and cancer | Dr Angela Alistar, MD, Oncologist in Morristown, NJ
#Immunoscore® Colon
Publication

#publication | Apr. 2020

Pages F, Andre T, Taieb J et al.

Prognostic and Predictive Value of the Immunoscore in Stage III Colon Cancer Patients Treated With Oxaliplatin in the Prospective IDEA France PRODIGE-GERCOR Cohort Study

Annals of Oncology

#Immunoscore® Colon
Publication

#publication | Apr. 2020

Sinicrope F, Shi Q, Hermitte F et al.

Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer

JNCI Cancer Spectrum

#Immunoscore® Colon
Publication

#publication | Mar. 2020

Blair H

Immunoscore®: A Diagnostic Assay for Clinical Management of Colon Cancer

Molecular Diagnosis & Therapy volume

#Immunoscore® Colon
Video

#video | Mar. 2020

Franck Pagès, MD, PhD, on Selecting Patients With Advanced Colon Cancer for Treatment
#Immunoscore® Colon
Poster

#poster | Jan. 2020

Poster presented at Gastro Intestinal Symposium #GI20

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (3 vs 6 months) in the prospective IDEA France cohort study

#Immunoscore® Colon
Publication

#publication | Jan. 2020

Pagès F, Kirilovsky A, Mlecnik B et al.

In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.

Journal of Clinical Oncology

#Immunoscore® Colon
Brochure

#brochure | Dec. 2019

Brochure Immunoscore® in Localized Colon Cancer

For Patients & Caregivers (English)

#Immunoscore® Colon
Brochure

#brochure | Dec. 2019

Brochure Immunoscore® in Localized Colon Cancer

For Healthcare Professionals (CLIA US version)

#Immunoscore® Colon
Brochure

#brochure | Dec. 2019

Brochure Immunoscore® in Localized Colon Cancer

For Healthcare Professionals (CE/IVD version)

#Immunoscore® Colon
Brochure

#brochure | Dec. 2019

Brochure Immunoscore® in Localized Colon Cancer

For Patients & Caregivers (Spanish)

#Immunoscore® Colon
Video

#video | Sep. 2019

Webinar Immunoscore®: IDEA France study results in Stage III Colon Cancer - Sept. 19, 2019 | Franck Pagès, Eric Van Cutsem
#Immunoscore® Colon
Publication

#publication | Aug. 2019

Angell HK, Bruni D, Barrett JC et al.

The Immunoscore: Colon Cancer and Beyond.

Clin Cancer Res.

#Immunoscore® Colon
Poster

#poster | Jul. 2019

Poster presented at ESMO GI 2019

Significant differences in outcome between Immunoscore categories in stage I colon cancer patients

#Immunoscore® Colon
Video

#video | Jun. 2019

Extract of an interview by Cancer.fr of Professor Thierry André, on Immunoscore® in the IDEA France study (in French)
#Immunoscore® Colon
Video

#video | Jun. 2019

Jérôme Galon, winner for the European Inventor Award 2019 for Immunoscore®
#Immunoscore® Colon
Poster

#poster | Jun. 2019

Poster presented at ASCO 2019

Validation of the Immunoscore Prognostic Value in Stage III Colon Cancer Patients treated with Oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).

#Immunoscore® Colon
Publication

#publication | May. 2019

Pages F, Andre T, Taieb J et al.

Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR)

Journal of Clinical Oncology

#Immunoscore® Colon
Video

#video | Apr. 2019

Dr. Fakih Discusses the Utility of Immunoscore® in CRC
#Immunoscore® Colon
Video

#video | Mar. 2019

Immunoscore® Webinar New data in Stage II Colon Cancer - March 21, 2019 | Jêrome Galon, PhD
#Immunoscore® Colon
Publication

#publication | Mar. 2019

Zeitoun G, Sissy CE, Kirilovsky A et al.

The Immunoscore in the Clinical Practice of Patients with Colon and Rectal Cancers.

Chirurgia (Bucur).

#Immunoscore® Colon
Video

#video | Jan. 2019

Discover how Immunoscore® is predicting the risk of relapse in localized colon cancer in a short video
#Immunoscore® Colon
Poster

#poster | Jan. 2019

Poster presented at Gastrointestinal Cancers Symposium 2019

Immunoscore clinical utility to identify good prognostic Colon Cancer Stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided

#Immunoscore® Colon
Poster

#poster | Dec. 2018

Poster presented at ESMO ASIA 2018

UCGI 34 - PROSCORE: A prospective study assessing whether Immunoscore® test impacts the choice of adjuvant chemotherapy, in a multidisciplinary meeting, for treating non-metastatic colon cancer patients after curative-intent surgery

#Immunoscore® Colon
Poster

#poster | Dec. 2018

Poster presented at ESMO IO 2018

MSI status plus Immunoscore to select metastatic colorectal cancer patients for immunotherapies

#Immunoscore® Colon
Poster

#poster | Nov. 2018

Poster presented at ESMO ASIA 2018

Immunoscore feasibility study in routine postsurgical pathologic review for early‐stage colon cancer (CC) cases risk‐assessment

#Immunoscore® Colon
Publication

#publication | Oct. 2018

Angelova M, Mlecnik B, Vasaturo A et al.

Evolution of Metastases in Space and Time under Immune Selection.

Cell

#Immunoscore® Colon
Video

#video | Aug. 2018

Webinar on “Clinical utility of Immunoscore® in colon cancer” with Marc Van Den Eynde, MD, PhD | October 17, 2017
#Immunoscore® Colon
Video

#video | Aug. 2018

Dr Jerome Galon on the Prognostic Value of Immunoscore, Onclive - ASCO 2016
#Immunoscore® Colon
Video

#video | Aug. 2018

Immunoscore® Colon Symposium - June 1, 2018, Chicago | Discussion on clinical cases
#Immunoscore® Colon
Video

#video | Aug. 2018

Immunoscore® Colon Symposium - June 1, 2018, Chicago | Jérôme Galon, PhD
#Immunoscore® Colon
Video

#video | Aug. 2018

Immunoscore® Colon Symposium - June 1, 2018, Chicago | Stanley Hamilton, MD
#Immunoscore® Colon
Publication

#publication | May. 2018

Pagès F, Mlecnik B, Marliot F et al.

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

Lancet

#Immunoscore® Colon
Poster

#poster | Feb. 2018

Poster presented at ASCO GI 2018

Immunoscore provides prognostic information in low (T3N1) and high (T4 or N2) risk subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial [NCCTG N0147 (Alliance)

#Immunoscore® Colon
Publication

#publication | Feb. 2018

Sinicrope F, Shi Q, Hermitte F et al.

Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

J Clin Oncol.

#Immunoscore® Colon
Publication

#publication | Jan. 2018

Mlecnik B, Van den Eynde M, Bindea G et al.

Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.

J Natl Cancer Inst.

#Immunoscore® Colon
Poster

#poster | Jun. 2017

Poster presented at ASCO 2017

Prognostic utility of immune markers and validation of Immunoscore® in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial [NCCTG N0147 (Alliance)]

#Immunoscore® Colon
Publication

#publication | May. 2017

Sinicrope F, Shi Q, Hermitte F et al.

Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).

J Clin Oncol.

#Immunoscore® Colon
Publication

#publication | May. 2017

Galon J, Mlecnik B, Marliot F et al.

Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.

J Clin Oncol.

#Immunoscore® Colon
Poster

#poster | Nov. 2016

Poster presented at SITC 2016

Immunoscore® analytical performance

#Immunoscore® Colon
Publication

#publication | Sep. 2016

Hermitte F

Biomarkers immune monitoring technology primer: Immunoscore® Colon.

Journal for ImmunoTherapy of Cancer

#Immunoscore® Colon
Publication

#publication | Aug. 2016

Kirilovsky A, Marliot F, El Sissy C et al.

Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.

Int Immunol.

#Immunoscore® Colon
Publication

#publication | Mar. 2016

Mlecnik B, Bindea G, Angell HK et al.

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.

Immunity

#Immunoscore® Colon
Publication

#publication | Feb. 2016

Mlecnik B, Bindea G, Kirilovsky A et al.

The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.

Sci Transl Med.

#Immunoscore® Colon
Publication

#publication | Feb. 2011

Mlecnik B, Tosolini M, Kirilovsky A et al.

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

Journal of Clinical Oncology

#Immunoscore® Colon
Publication

#publication | Sep. 2006

Galon J, Costes A, Sanchez-Cabo F et al.

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Science


Contact us

 
   

By subscribing to our newsletter, you accept to receive information on our news and events by email. You can unsubscribe any time by clicking on the unsubscribe link at the bottom of our newsletters, or by sending us an unsubscribe request at privacy(at)haliodx(dot)com.

Book an online appointment with our team

   

Please provide us your time zone

Please propose 2/3 options for this online meeting


Fields marked with an asterisk (*) are required!

The information about you collected through this form is used by HalioDx to handle your request. Fields with an asterisk are mandatory. Otherwise, your request for information cannot be processed.
Your data will be processed by HalioDx authorized services, and might be transmitted to external service providers processing your data on behalf of HalioDx. For more information on protection mechanisms implemented, please contact the data Protection Officer: privacy(at)haliodx(dot)com.

As HalioDx contacts, your personal data are stored in our database system as long as your subscription to the newsletter or email services is active. Any recipient may request at any time to be removed from our contact database by writing an email to privacy(at)haliodx(dot)com with “I wish to be removed from your contact Database” in your subject line and we will comply with that request.

HalioDx newsletter subscription


Join our newsletter and be the first to get notified on new updates.


× Hide this popup.